Skip to main content

Table 3 Characteristics that are statistically different between patients with high serum TNC and high serum periostin levels and others

From: Characterization of tenascin-C as a novel biomarker for asthma: utility of tenascin-C in combination with periostin or immunoglobulin E

  High TNC > 37.16 Low TNC < 37.16 High TNC > 37.16 Low TNC < 37.16 P value for multigroup analysis Groups B, C and D P value between groups A and E
High periostin > 95 High periostin > 95 Low periostin < 95 Low periostin < 95
A (n = 20) B (n = 21) C (n = 32) D (n = 53) E (n = 106)
GINA step 4 + 5, n (%) 17 (85.0) 7 (33.3) 25 (78.1) 32 (60.4) 0.001* 64 (60.4) 0.042*
AERD, n (%) 6 (30.0) 0 (0.0) 1 (3.1) 5 (9.4) 0.004* 6 (5.7) 0.004*
Daily dose of ICS (FP equivalent dose, µg) 735.00 ± 346.83 392.86 ± 346.51 629.69 ± 349.39 575.47 ± 407.10 0.021* 555.66 ± 384.91 0.045*
FeNO (ppb) 65.30 ± 46.36 65.87 ± 34.04 54.51 ± 52.86 47.21 ± 39.25 0.033* 53.11 ± 43.12 0.208
Peripheral neutrophils (cells/μL) 4588.06 ± 1452.31 3496.31 ± 1052.69 4216.49 ± 1600.66 3900.12 ± 1535.39 0.037* 3915.63 ± 1482.52 0.032*
Peripheral eosinophils (cells/μL) 423.03 ± 315.58 354.16 ± 243.56 223.62 ± 224.07 191.55 ± 159.50 0.001* 233.44 ± 206.28 0.005*
Serum periostin (ng/mL) 138.65 ± 37.94 114.33 ± 17.18 67.81 ± 15.66 69.81 ± 14.82 < 0.001* 78.03 ± 23.81 < 0.001*
Serum TNC (ng/mL) 57.93 ± 18.62 25.42 ± 8.56 62.44 ± 29.95 24.25 ± 7.94 < 0.001* 36.01 ± 24.80 < 0.001*
FVC (L) 2.72 ± 0.93 3.17 ± 0.86 3.38 ± 0.89 3.34 ± 0.98 0.063 3.32 ± 0.93 0.010*
%FVC (predicted, %) 96.10 ± 9.38 103.77 ± 16.30 102.95 ± 16.61 105.47 ± 17.57 0.118 104.37 ± 16.92 0.019*
FEV1 (L) 1.99 ± 0.80 2.28 ± 0.59 2.47 ± 0.83 2.52 ± 0.80 0.062 2.46 ± 0.77 0.014*
PEF (L/s) 6.39 ± 2.00 6.92 ± 1.42 7.46 ± 2.35 7.54 ± 2.05 0.142 7.39 ± 2.04 0.045*
MMF (L) 1.51 ± 1.01 1.64 ± 0.69 1.99 ± 1.07 2.21 ± 1.14 NS 2.03 ± 1.06 0.045*
%MMF (predicted, %) 48.14 ± 24.36 54.37 ± 20.36 56.33 ± 26.21 66.39 ± 30.28 NS 60.97 ± 27.67 0.042*
  1. Data are presented as the mean ± standard deviation unless otherwise indicated
  2. ACT asthma control test, AERD aspirin-exacerbated respiratory disease, BMI body mass index, FeNO fractional exhaled nitric oxide, FEV1 forced expiratory volume in 1 s, FP fluticasone propionate, FVC forced vital capacity, GINA Global Initiative for Asthma, ICS inhaled corticosteroid, IgE immunoglobulin E, MMF mid-maximal flow rate, OCS oral corticosteroids, PEF peak expiratory flow, PSL prednisolone, Th2 T-helper cell type 2, TNC tenascin-C, NS not significant
  3. *P < 0.05
  4. Multigroup analysis performed by Chi square test, One-way ANOVA and Kruskal–Wallis test as appropriate
  5. Comparisons performed by Student’s t test, the Mann–Whitney U test, and Fisher’s exact test as appropriate
\